Get the Stockscreener App
3.20
11.60%
-0.42
After Hours:
3.21
0.010
+0.31%
Salarius Pharmaceuticals Inc stock is traded at $3.20, with a volume of 85,140.
It is down -11.60% in the last 24 hours and down -17.74% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$3.62
Open:
$3.66
24h Volume:
85,140
Relative Volume:
0.41
Market Cap:
$1.63M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.4984
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
-14.09%
1M Performance:
-17.74%
6M Performance:
-69.08%
1Y Performance:
-85.29%
1-Day Range:
$3.18
$3.66
1-Week Range:
$3.18
$3.94
52-Week Range:
$3.1601
$108.00
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
3.20 | 3.81M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Technical analysis overview for Salarius Pharmaceuticals Inc. stockSwing Trade & Fast Gain Stock Tips - newser.com
Can Salarius Pharmaceuticals Inc. (FP10) stock expand revenue streamsMarket Volume Report & Entry Point Confirmation Signals - newser.com
Trend analysis for Salarius Pharmaceuticals Inc. this weekJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
How Salarius Pharmaceuticals Inc. (FP10) stock reacts to Fed tighteningWeekly Market Summary & Advanced Technical Analysis Signals - newser.com
Does Salarius Pharmaceuticals Inc. show high probability of reboundDividend Hike & Momentum Based Trading Ideas - newser.com
Will Salarius Pharmaceuticals Inc. stock see insider buyingMarket Movement Recap & Weekly Market Pulse Alerts - newser.com
Analyzing net buyer seller activity in Salarius Pharmaceuticals Inc.2025 Technical Overview & Growth Focused Stock Reports - newser.com
Applying chart zones and confluence areas to Salarius Pharmaceuticals Inc.July 2025 Trends & Target Return Focused Stock Picks - newser.com
What’s the recovery path for long term holders of Salarius Pharmaceuticals Inc.Quarterly Earnings Summary & Long-Term Capital Growth Strategies - newser.com
Ranking Salarius Pharmaceuticals Inc. among high performing stocks via tools2025 Volatility Report & Verified Entry Point Detection - newser.com
How big funds are accumulating Salarius Pharmaceuticals Inc. (FP10) stockJuly 2025 Levels & Proven Capital Preservation Tips - newser.com
What risks investors should watch in Salarius Pharmaceuticals Inc. stockPortfolio Risk Report & Free Expert Verified Stock Movement Alerts - newser.com
Will Salarius Pharmaceuticals Inc. stock benefit from green energy trends2025 Support & Resistance & Weekly Momentum Picks - newser.com
How Salarius Pharmaceuticals Inc. stock benefits from tech adoptionMarket Risk Report & Daily Stock Momentum Reports - newser.com
How Salarius Pharmaceuticals Inc. (FP10) stock moves on employment dataJuly 2025 Update & AI Powered Market Entry Strategies - newser.com
Intraday pattern recognizer results for Salarius Pharmaceuticals Inc.2025 Analyst Calls & Safe Entry Point Identification - newser.com
What catalysts could drive Salarius Pharmaceuticals Inc. stock higherM&A Rumor & Safe Swing Trade Setups - newser.com
Is now a turning point for Salarius Pharmaceuticals Inc.July 2025 Pullbacks & Expert Verified Movement Alerts - newser.com
When is the best time to exit Salarius Pharmaceuticals Inc.July 2025 Reactions & Real-Time Stock Movement Alerts - newser.com
Published on: 2025-11-03 03:25:06 - newser.com
Why Salarius Pharmaceuticals Inc. (FP10) stock stays on top picksQuarterly Earnings Report & Long Hold Capital Preservation Plans - newser.com
Will Salarius Pharmaceuticals Inc. (FP10) stock keep raising dividendsQuarterly Growth Report & Weekly High Return Opportunities - newser.com
Applying Elliott Wave Theory to Salarius Pharmaceuticals Inc.Market Growth Review & AI Driven Stock Reports - newser.com
Why Salarius Pharmaceuticals Inc. (FP10) stock could break out in 2025July 2025 Summary & Proven Capital Preservation Tips - newser.com
Published on: 2025-11-01 04:32:37 - newser.com
Salarius Pharmaceuticals Awaits Nasdaq Compliance Confirmation - MSN
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):